

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors of Livzon Pharmaceutical Group Inc.* (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 23 October 2026, for the purpose of of, among other matters, considering and approving the unaudited third quarterly results of 2026 of the Company and its subsidiaries for the nine months ended September 30, 2026 and the payment of dividend for the first three quarters (if any) and transacting any other business.

By order of the Board

麗珠醫藥集團股份有限公司

Livzon Pharmaceutical Group Inc.*

Liu Ning

Company Secretary

Zhuhai, China

12 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (Chairman and President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

** For identification purposes only*